Corbus Pharmaceuticals Holdings (STU:3371) Shares Outstanding (EOP): 17.74 Mil (As of Mar. 2026)


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €7.93
GF Value €0.40
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Shares Outstanding (EOP)?

Corbus Pharmaceuticals Holdings STU:3371 -2.04% 31 Shares Outstanding (EOP) is 17.74 Mil as of Mar. 2026. GuruFocus rates STU:3371 with a GF Score™ of 31/100 and a GF Value™ of €0.40 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Corbus Pharmaceuticals Holdings's shares outstanding for the quarter that ended in Mar. 2026 was 17.74 Mil.

Corbus Pharmaceuticals Holdings's quarterly shares outstanding increased from Dec. 2025 (17.61 Mil) to Mar. 2026 (17.74 Mil). It means Corbus Pharmaceuticals Holdings issued new shares from Dec. 2025 to Mar. 2026 .

Corbus Pharmaceuticals Holdings's annual shares outstanding increased from Dec. 2024 (12.18 Mil) to Dec. 2025 (17.61 Mil). It means Corbus Pharmaceuticals Holdings issued new shares from Dec. 2024 to Dec. 2025 .


Corbus Pharmaceuticals Holdings  (STU:3371) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Corbus Pharmaceuticals Holdings Shares Outstanding (EOP) Related Terms


Corbus Pharmaceuticals Holdings Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Shares Outstanding (EOP) Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.17 4.17 4.42 12.18 17.61

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.23 12.25 12.54 17.61 17.74

STU:3371 vs PRQR, NRXP, CRBU: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Shares Outstanding (EOP) falls into.


STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 17.74 Mil mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a Shares Outstanding (EOP) of 17.74 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Shares Outstanding (EOP) too high?
Corbus Pharmaceuticals Holdings' current Shares Outstanding (EOP) is 17.74 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Shares Outstanding (EOP) compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Shares Outstanding (EOP) of 17.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Shares Outstanding (EOP) is 17.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (STU:3371) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.40, compared to a current price of €7.93 — trading 1881.3% above its estimated fair value. The current Shares Outstanding (EOP) is 17.74 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Shares Outstanding (EOP) is 17.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corbus Pharmaceuticals Holdings (STU:3371) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of €7.93 is trading 1881.3% above its estimated GF Value™ of €0.40. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for STU:3371:

  • Shares Outstanding (EOP): 17.74 Mil
  • GF Value™: €0.40 vs. price of €7.93 (1881.3% above fair value)
  • GF Score™: 31/100 with 1 warning sign

No single metric tells the full story. See the STU:3371 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.93
Price
€0.40
GF Value